Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

A prospective study of radioimmunoscintigraphy in ovarian cancer

Conference · · J. Nucl. Med.; (United States)
OSTI ID:7031989

The aim of this first prospective study using a monoclonal antibody labelled with I-123 was to determine its clinical potential. 30 patients with pelvic tumour, diagnosis known only to the gynaecological oncologists were referred and imaged at 10 min, 4h and 22h using human milk fat globule monoclonal antibody HMFG2 labelled using the iodogen technique with pure I-123 (2.5mCi injected). Images were reported without clinical information as negative or positive for ovarian cancer OC and its distribution mapped. Surgery and histology were assessed independently by the oncologists and the patients finally classified into group I: 10 with benign or non ovarian malignant disease and group II: 20 with OC in whom the sites of biopsy positive disease were also mapped. In group 1 5/10 patients showed the pattern of OC indicating that the technique is unsuccessful as a screening test due to the lack of specificity - uptake by liver, stomach and colon metastases being seen. In group II the distribution of OC primary and metastases was correct in 18/20, 90%. A new technique based on the kinetics of antibody uptake by the tumour using an algorithm which converts the data to a probability map based on the significance of the differences in distribution between the early and later images, correctly localised two 0.5cm biopsy positive OC tumours in one of the failures in group II. These results slow that radioimmunoscintigraphy will contribute to staging and evaluating chemotherapy in known OC.

Research Organization:
St. Bartholomew's Hospital, London
OSTI ID:
7031989
Report Number(s):
CONF-850611-
Journal Information:
J. Nucl. Med.; (United States), Journal Name: J. Nucl. Med.; (United States) Vol. 26:5; ISSN JNMEA
Country of Publication:
United States
Language:
English